Cannabis RegulationGovernment & regulators

Department of Thai Traditional Medicine

The Department of Thai Traditional Medicine refers to Thailand’s traditional-medicine public-health function involved in the medical framing of cannabis policy. In cannabis reports, it is relevant because Thailand’s legal pathway emphasized medical and traditional uses rather than a purely recreational market. Its role is regulatory and administrative: setting or supporting rules, programmes, compliance expectations, and acceptable use cases. Operators are affected by this framework through licensing, product positioning, medical documentation, cultivation standards, and the distinction between compliant medical activity and prohibited recreational sales.

Profile overview

The Department of Thai Traditional Medicine refers to Thailand’s traditional-medicine public-health function involved in the medical framing of cannabis policy. In cannabis reports, it is relevant because Thailand’s legal pathway emphasized medical and traditional uses rather than a purely recreational market. Its role is regulatory and administrative: setting or supporting rules, programmes, compliance expectations, and acceptable use cases. Operators are affected by this framework through licensing, product positioning, medical documentation, cultivation standards, and the distinction between compliant medical activity and prohibited recreational sales.

Public-record references
Data as of: 2024-2026

Regulatory program areas

Medical cannabis framework

Traditional medicine pathway licensing

The department administers the traditional-medicine lens of Thailand's cannabis policy, treating cannabis flower as a controlled herb under the Traditional Medicine Wisdom Protection and Promotion Act rather than under the Narcotics Code. This classification defines which practitioners, programmes, and dispensary formats can legally operate post-2025 recriminalisation.

Prescription gating

30-day prescription requirement

Under the June 2025 cannabis notification, patients must obtain a prescription valid for 30 days from a licensed traditional or modern medicine practitioner to access cannabis flower legally. The prescription regime is the primary commercial gating mechanism determining which dispensaries can operate and which patient populations can access product.

Traditional medicine integration

Cannabis in Thai herbal medicine

The department supports research and clinical development of cannabis as an ingredient in Thai traditional herbal preparations, including pain relief, appetite stimulation, and nausea management. GPO's medical-cannabis programme and licensed hospital dispensing sit within this traditional-medicine legitimacy frame.

Enforcement coordination

Distinction between herb and narcotic

Cannabis flower is classified as a controlled herb; extracts with THC exceeding 0.2% remain narcotics under the Narcotics Code. The department coordinates with MoPH enforcement agencies to maintain this classification distinction, which determines whether informal dispensaries face administrative or criminal penalties.

Thailand cannabis regulation timeline and status

Cannabis decriminalisation

Date

June 2022

Impact on operators

Flower removed from narcotics list; dispensary boom

Reclassification as controlled herb

Date

Late 2024

Impact on operators

Medical/traditional use only; prescription requirement emerging

June 2025 notification — 30-day prescription regime

Date

June 2025

Impact on operators

7,000+ dispensaries forced to close or convert to medical model

GPO medical-cannabis programme ongoing

Date

Ongoing

Impact on operators

State-produced medical-grade cannabis; benchmark for legitimate supply

Extracts (>0.2% THC) — narcotics classification maintained

Date

Ongoing

Impact on operators

Extracts remain prohibited without specific medical exemption

Watchpoints 2025-2026

Enforcement

Prescription-regime compliance

7,000-plus dispensaries closed or converted following the June 2025 notification. Enforcement consistency across Bangkok, tourist areas, and provincial markets will determine how many informal operators continue selling without prescriptions, undermining the medical-only framework.

GPO programme

State medical cannabis supply

Government Pharmaceutical Organisation (GPO) medical cannabis products are the benchmark for legitimate, regulated supply. If GPO production capacity is insufficient to meet licensed practitioner prescription demand, shortfalls could create informal substitution channels that blur the medical-only boundary.

Legal evolution

Cannabis Act drafting

A dedicated Cannabis Act to replace the current ministerial-notification approach was under discussion as of 2025. The Act's provisions on recreational use, tourist exemptions, and export rights will determine the long-term regulatory ceiling for the Thai cannabis industry.

Source-pack context

Department of Thai Traditional Medicine is linked to existing Insight report coverage through tracked source packs. The cited sources provide the current evidence trail for market context, regulatory exposure, operator positioning, or sector structure; exact numeric claims should still be checked against raw snapshots before being surfaced as headline metrics.[, , ]

Deep operating read

The Department of Thai Traditional Medicine is the medical / traditional-use policy layer in Thailand's cannabis reversal. The source pack frames the arc from June 2022 decriminalisation to 2024/2025 recriminalisation and medical-only gating, with cannabis flower reclassified as a controlled herb under the Thai Traditional Medicine Wisdom Protection and Promotion Act. Its operating relevance is rule-setting: prescriptions, practitioner channels, acceptable medical use cases and compliance expectations determine which dispensaries survive.[, , ]

Execution watchpoints

Watch enforcement of the 30-day prescription regime, licensed-practitioner gating and the distinction between controlled-herb flower and >0.2% THC extracts treated as narcotic. Nation Thailand quantifies the industry shock as 7,000+ dispensaries closing between the June 2025 notification and early 2026. The GPO medical-cannabis programme remains the state-production comparator for medical-only legitimacy.[, , , ]

Related Market profiles

Peers, parents, partners, agencies, and other Cannabis Regulation actors.

Reports featuring this profile

Related Market profiles

Department of Thai Traditional Medicine - Market Atlas · Insight